Business
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) anticipated in 2026 Expanded NexoBrid® manufacturing facility fully operational; regulatory approvals targeted for 2026 $17 million in 2025 revenue; financial guidance updated to $24–26 mi
About this update from Mediwound Ltd.
[{"type":"image","alt":"MediWound Ltd.","displaySize":"","headline":null,"caption":"MediWound Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lMBSATvDCuA9PnawJVvewQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159","width":300,"height":113}},"lazy":false},{"type":"text","content":"MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference","length":104,"tagName":"p"},{"type":"text","content":"Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) anticipated in 2026","length":226,"tagName":"p"},{"type":"text","content":"Expanded NexoBrid® manufacturing facility fully operational; regulatory approvals targeted for 2026","length":99,"tagName":"p"},{"type":"text","content":"$17 million in 2025 revenue; financial guidance updated to $24–26 million (2026), $32–35 million (2027), and $50–55 million (2028); $54 million cash position","length":157,"tagName":"p"},{"type":"text","content":"YAVNE, Israel, January 12, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today provided a corporate and financial update ahead of its participation in the J.P. Morgan Healthcare Conference.","length":259,"tagName":"p"},{"type":"text","content":"“As we enter 2026, we are encouraged by the momentum we’ve built as we continue to execute on our growth strategy, with meaningful progress across both our clinical pipeline and operational platform,” said Ofer Gonen, Chief Executive Officer of MediWound. “Over the past year, we advanced our Phase III VALUE trial toward key milestones, positioned the EscharEx® program for expansion into additional chronic wound indications, strengthened our balance sheet, and completed the expansion of our NexoBrid® manufacturing facility, which is now fully operational. While U.S. government shutdown–related delays impacted revenue recognition in our fourth quarter results, and certain activities are still pending, we believe these ...